Avita Therapeutics/$RCEL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Avita Therapeutics
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.
Ticker
$RCEL
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
260
ISIN
US05380C1027
Website
RCEL Metrics
BasicAdvanced
$152M
-
-$2.19
1.55
-
Price and volume
Market cap
$152M
Beta
1.55
52-week high
$14.16
52-week low
$5.46
Average daily volume
300K
Financial strength
Current ratio
2.09
Quick ratio
1.654
Long term debt to equity
-964.187
Total debt to equity
-964.187
Interest coverage (TTM)
-0.24%
Management effectiveness
Return on assets (TTM)
-38.35%
Return on equity (TTM)
-407.50%
Valuation
Price to revenue (TTM)
2.089
Price to book
-33.25
Price to tangible book (TTM)
-15.17
Price to free cash flow (TTM)
-3.204
Growth
Revenue change (TTM)
41.35%
Earnings per share change (TTM)
24.36%
3-year revenue growth (CAGR)
31.11%
3-year earnings per share growth (CAGR)
24.02%
What the Analysts think about RCEL
Analyst ratings (Buy, Hold, Sell) for Avita Therapeutics stock.
RCEL Financial Performance
Revenues and expenses
RCEL Earnings Performance
Company profitability
RCEL News
AllArticlesVideos
AVITA Medical's RECELL Platform Recognized for Surgical Innovation in 2025 MedTech Breakthrough Awards
GlobeNewsWire·2 days ago
AVITA Medical to Announce First Quarter 2025 Financial Results
GlobeNewsWire·2 months ago
AVITA Medical to Present Breakthrough Clinical Data in Burn and Wound Care at ABA 2025
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Avita Therapeutics stock?
Avita Therapeutics (RCEL) has a market cap of $152M as of June 06, 2025.
What is the P/E ratio for Avita Therapeutics stock?
The price to earnings (P/E) ratio for Avita Therapeutics (RCEL) stock is 0 as of June 06, 2025.
Does Avita Therapeutics stock pay dividends?
No, Avita Therapeutics (RCEL) stock does not pay dividends to its shareholders as of June 06, 2025.
When is the next Avita Therapeutics dividend payment date?
Avita Therapeutics (RCEL) stock does not pay dividends to its shareholders.
What is the beta indicator for Avita Therapeutics?
Avita Therapeutics (RCEL) has a beta rating of 1.55. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.